Suppr超能文献

醋酸环丙孕酮或螺内酯对接受雌二醇治疗的跨性别者降低睾酮浓度的作用。

Cyproterone acetate or spironolactone in lowering testosterone concentrations for transgender individuals receiving oestradiol therapy.

作者信息

Angus Lachlan, Leemaqz Shalem, Ooi Olivia, Cundill Pauline, Silberstein Nicholas, Locke Peter, Zajac Jeffrey D, Cheung Ada S

机构信息

Department of Medicine (Austin Health), The University of Melbourne, Heidelberg, Victoria, Australia.

Robinson Research Institute, Adelaide Medical School, The University of Adelaide, Adelaide, South Australia.

出版信息

Endocr Connect. 2019 Jul;8(7):935-940. doi: 10.1530/EC-19-0272.

Abstract

BACKGROUND

Oestradiol with or without an anti-androgen (cyproterone acetate or spironolactone) is commonly prescribed in transfeminine individuals who have not had orchidectomy; however, there is no evidence to guide optimal treatment choice.

OBJECTIVE

We aimed to compare add-on cyproterone acetate versus spironolactone in lowering endogenous testosterone concentrations in transfeminine individuals.

DESIGN

Retrospective cross-sectional study.

METHODS

We analysed 114 transfeminine individuals who had been on oestradiol therapy for >6 months in two gender clinics in Melbourne, Australia. Total testosterone concentrations were compared between three groups; oestradiol alone (n = 21), oestradiol plus cyproterone acetate (n = 21) and oestradiol plus spironolactone (n = 38). Secondary outcomes included serum oestradiol concentration, oestradiol valerate dose, blood pressure, serum potassium, urea and creatinine.

RESULTS

Median age was 27.0 years (22.5-45.1) and median duration of hormone therapy was 1.5 years (0.9-2.6), which was not different between groups. On univariate analysis, the cyproterone group had significantly lower total testosterone concentrations (0.8 nmol/L (0.6-1.20)) compared with the spironolactone group (2.0 nmol/L (0.9-9.4), P = 0.037) and oestradiol alone group (10.5 nmol/L (4.9-17.2), P < 0.001), which remained significant (P = 0.005) after adjustments for oestradiol concentration, dose and age. Serum urea was higher in the spironolactone group compared with the cyproterone group. No differences were observed in total daily oestradiol dose, blood pressure, serum oestradiol, potassium or creatinine.

CONCLUSIONS

The cyproterone group achieved serum total testosterone concentrations in the female reference range. As spironolactone may cause feminisation without inhibition of steroidogenesis, it is unclear which anti-androgen is more effective at feminisation. Further prospective studies are required.

摘要

背景

对于未进行睾丸切除术的跨性别女性个体,通常会开具含或不含抗雄激素(醋酸环丙孕酮或螺内酯)的雌二醇处方;然而,尚无证据指导最佳治疗选择。

目的

我们旨在比较添加醋酸环丙孕酮与螺内酯降低跨性别女性个体内源性睾酮浓度的效果。

设计

回顾性横断面研究。

方法

我们分析了在澳大利亚墨尔本的两家性别诊所接受雌二醇治疗超过6个月的114名跨性别女性个体。比较了三组的总睾酮浓度;单独使用雌二醇组(n = 21)、雌二醇加醋酸环丙孕酮组(n = 21)和雌二醇加螺内酯组(n = 38)。次要结局包括血清雌二醇浓度、戊酸雌二醇剂量、血压、血清钾、尿素和肌酐。

结果

中位年龄为27.0岁(22.5 - 45.1),激素治疗的中位持续时间为1.5年(0.9 - 2.6),各组之间无差异。单因素分析显示,与螺内酯组(2.0 nmol/L(0.9 - 9.4),P = 0.037)和单独使用雌二醇组(10.5 nmol/L(4.9 - 17.2),P < 0.001)相比,醋酸环丙孕酮组的总睾酮浓度显著更低(0.8 nmol/L(0.6 - 1.20)),在对雌二醇浓度、剂量和年龄进行调整后,差异仍然显著(P = 0.005)。与醋酸环丙孕酮组相比,螺内酯组的血清尿素更高。在每日总雌二醇剂量、血压、血清雌二醇、钾或肌酐方面未观察到差异。

结论

醋酸环丙孕酮组的血清总睾酮浓度达到了女性参考范围。由于螺内酯可能在不抑制类固醇生成的情况下导致女性化,目前尚不清楚哪种抗雄激素在女性化方面更有效。需要进一步的前瞻性研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d99/6612061/365d7274be17/EC-19-0272fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验